according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Ezetimibe Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Ezetimibe Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A
	Telephone	:	+1-551-430-6000
	E-mail address of person	:	EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

responsible for the SDS

+1-215-631-6999

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008) Long-term (chronic) aquatic hazard, Category 2

#### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	¥_2	
Hazard statements	:	H411	Toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention P273	: Avoid release to the environment.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Ezetimibe Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

### Response:

P391 Collect spillage.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

Components Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ezetimibe	163222-33-1	Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1	>= 10 - < 20
Sodium n-dodecyl sulfate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412 specific concentration limit Eye Irrit. 2; H319 10 - < 20 % Eye Dam. 1; H318 >= 20 % Acute toxicity estimate	>= 1 - < 2.5

### 3.2 Mixtures

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Ezetimibe Formulation

Version 4.2	n Revision Date: SDS Number: 06.04.2024 23833-00024		Date of last issue: 26.09.2023 Date of first issue: 21.10.2014		
			Acute oral toxicity: 1,200 mg/kg		
2-Pyr	rolidone	616-45-5 210-483-1	Eye Irrit. 2; H319 Repr. 1B; H360FD specific concentration	>= 0.1 - < 0.3	
			limit Repr. 1B; H360FD > 3 %		

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
4.2 Most important symptoms a	nd e	effects, both acute and delayed
Risks	:	Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment	: Treat symptomatically and supportively.
-----------	---

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Ezetimibe Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

### **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing	:	None known.

#### 5.2 Special hazards arising from the substance or mixture

5.2 Special nazarus ansing nom	une	
Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx) Fluorine compounds Sulphur oxides Metal oxides
5.3 Advice for firefighters		
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Ezetimibe Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

### 6.3 Methods and material for containment and cleaning up

•
<ul> <li>Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding</li> </ul>
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion.
	Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not get on skin or clothing.
	Do not breathe dust.
	Do not swallow.
	Avoid contact with eyes.
	Handle in accordance with good industrial hygiene and safety
	practice, based on the results of the workplace exposure as- sessment
	Minimize dust generation and accumulation.
	Keep container closed when not in use.
	Keep away from heat and sources of ignition.
	Take precautionary measures against static discharges.
	Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye
	flushing systems and safety showers close to the working
	place. When using do not eat, drink or smoke. Wash contami-
	nated clothing before re-use.
	The effective operation of a facility should include review of
	engineering controls, proper personal protective equipment,
	appropriate degowning and decontamination procedures,
	industrial hygiene monitoring, medical surveillance and the
	use of administrative controls.
7.2 Conditions for safe storage, in	cluding any incompatibilities
De autore entre fan atamana	Keep in an activity of a state in any Oten a in a second second the

Requirements for storage	:	Keep in properly labelled containers. Store in accordance with
areas and containers		the particular national regulations.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Ezetimibe Formulation**

Version 4.2	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014	
Adv	ice on common storage	: Do not store w Strong oxidizir	vith the following product types: ng agents	
•	cific end use(s) cific use(s)	: No data availa	ble	

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

dusts non-specific

### **Occupational Exposure Limits**

4 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust) Basis: IE OEL

> 10 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust) Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
Ezetimibe	163222-33- 1	TWA	25 µg/m3 (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stea- rate	557-04-0	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m3
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m3
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	24 mg/kg bw/day
2-Pyrrolidone	Workers	Inhalation	Long-term systemic effects	57.8 mg/m3
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Ezetimibe Formulation

Vers 4.2	ion Revision Date: 06.04.2024	SDS Nur 23833-00		Date of last issue: 26.09.2023 Date of first issue: 21.10.2014		
		Workers	Skin cont	act	Acute systemic ef- fects	277 mg/kg bw/day
		Consumers	Inhalatior	٦	Long-term systemic effects	17.1 mg/m3
		Consumers	Skin cont	act	Long-term systemic effects	6 mg/kg bw/day
		Consumers	Skin cont	act	Acute systemic ef- fects	167 mg/kg bw/day
		Consumers	Ingestion		Long-term systemic effects	5.2 mg/kg bw/day
		Consumers	Ingestion		Acute systemic ef- fects	33.3 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium n-dodecyl sulfate	Fresh water	0.176 mg/l
	Marine water	0.018 mg/l
	Sewage treatment plant	1.35 mg/l
	Fresh water sediment	6.97 mg/kg dry weight (d.w.)
	Marine sediment	0.697 mg/kg dry weight (d.w.)
	Soil	1.29 mg/kg dry weight (d.w.)
2-Pyrrolidone	Fresh water	0.5 mg/l
	Freshwater - intermittent	0.5 mg/l
	Marine water	0.05 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	0.4205 mg/kg dry weight (d.w.)
	Soil	0.0612 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source

and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Ezetimibe Formulation**

Version 4.2	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014	
	emarks and body protection	: Work uniform Additional boo task being pe posable suits	<ul> <li>Consider double gloving.</li> <li>Work uniform or laboratory coat.</li> <li>Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.</li> <li>Use appropriate degowning techniques to remove potentially</li> </ul>	
	iratory protection ter type	contaminated : If adequate lo sure assessm ommended g Equipment sh		

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	off-white
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
рН	:	No data available
Viscosity		

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Ezetimibe Formulation**

	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014	DS Number: 3833-00024		Revision Date: 06.04.2024	Version 4.2
	9	No data available	:	scosity, kinematic	Visc
		No data available	:	bility(ies) /ater solubility	
	9	No data available	:	ion coefficient: n- nol/water	
	9	No data available	:	our pressure	Vapour
	9	No data available	:	ive density	Relative
	9	No data available	:	ity	Density
	9	No data available	:	ive vapour density	Relative
	9	No data available	:	cle characteristics article size	
				information	
		Not explosive	:	DSIVES	Explosi
ing.	r mixture is not classified as oxidizing.	The substance o	:	zing properties	Oxidizir
	9	No data available	:	oration rate	Evapora
		No data available	:	cular weight	Molecu
ing.	e e e e e e e e e e e e e e e e e e e	<ul> <li>No data available</li> <li>No tata available</li> <li>Not explosive</li> <li>The substance o</li> <li>No data available</li> </ul>		bility(ies) (ater solubility ater solu	Solubili Wat Partition octanol Vapour Relative Density Relative Particle Part 9.2 Other in Explosi Oxidizir

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

### **10.2 Chemical stability**

Stable under normal conditions.

10.3 Possibility of hazardous reaction	ons
Hazardous reactions :	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid :	Heat, flames and sparks. Avoid dust formation.
10.5 Incompatible materials	
Materials to avoid :	Oxidizing agents

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Ezetimibe Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

	ation on likely routes of		<b>as defined in Regulation (EC) No 1272/2008</b> Inhalation Skin contact Ingestion Eye contact
	toxicity		
Not cla	assified based on availa	ble	information.
Produ			
Acute	oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Comp	onents:		
Ezetim	nibe:		
Acute	oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
			LD50 (Mouse): > 5,000 mg/kg
			LD50 (Dog): > 3,000 mg/kg
Acute	inhalation toxicity	:	Remarks: No data available
Acute	dermal toxicity	:	Remarks: No data available
	toxicity (other routes of stration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal
			LD50 (Mouse): > 1,000 - < 2,000 mg/kg Application Route: Intraperitoneal
Sodiu	m n-dodecyl sulfate:		
Acute	oral toxicity	:	LD50 (Rat): 1,200 mg/kg Method: OECD Test Guideline 401
Acute	dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Remarks: Based on data from similar materials
2-Pyrr	olidone:		
-	oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 401 Assessment: The substance or mixture has no acute oral tox- icity

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Ezetimibe Formulation**

sion	Revision Date: 06.04.2024	-	98 Number: 833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
Acute	dermal toxicity	:		> 2,000 mg/kg ) Test Guideline 402 he substance or mixture has no acute derma
	corrosion/irritation			
	assified based on ava	ilable	information.	
	oonents:			
Ezeti			<b>D</b> 11 %	
Speci Resul		:	Rabbit No skin irritatio	n
Sodiu	Im n-dodecyl sulfate	:		
Speci		:	Rabbit	
Resul	t	:	Skin irritation	
-	rolidone:			
Speci Metho		:	Rabbit OECD Test Gu	idalina 101
Resul		:	No skin irritatio	
Not cl	us eye damage/eye i assified based on ava ponents: mibe:			
Speci		:	Rabbit	
Resul		:	No eye irritatio	1
Sodiu	Im n-dodecyl sulfate	:		
Speci			Rabbit	
Metho		•		
Resul	bd	:	OECD Test Gu Irreversible effe	
	bd	:		
<b>2-Pyr</b> Speci	od t <b>rolidone:</b> es	:	Irreversible effe	ects on the eye
2-Pyr	od t <b>rolidone:</b> es		Irreversible effe	
<b>2-Pyr</b> Speci Resul	od t <b>rolidone:</b> es	:	Irreversible effe Rabbit Irritation to eye	ects on the eye
<b>2-Pyr</b> Speci Resul <b>Resp</b>	od t <b>rolidone:</b> es t	:	Irreversible effe Rabbit Irritation to eye	ects on the eye
2-Pyr Speci Resul Resp Skin s	od t <b>rolidone:</b> es t i <b>ratory or skin sensit</b>	: isatio	Irreversible effe Rabbit Irritation to eye	ects on the eye

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



sion	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
Comp	oonents:		
Ezetir	nibe:		
Test T	Гуре	: Maximisation 7	Fest
Specie		: Guinea pig	
Result	t	: negative	
Sodiu	Im n-dodecyl sulfate	e:	
Test T	Гуре	: Maximisation 7	Fest
Expos	sure routes	: Skin contact	
Specie		: Guinea pig	
Result		: negative	
Rema	irks	: Based on data	from similar materials
2-Pyrı	rolidone:		
Test T	Гуре	: Local lymph no	ode assay (LLNA)
	sure routes	: Skin contact	
Specie	es	: Mouse	
Metho		: OECD Test Gu	uideline 429
Result		: negative	<b>*</b> • • • • • •
Rema	IſKS	: Based on data	from similar materials
Rema <b>Germ</b> Not cla	cell mutagenicity assified based on ava		from similar materials
Rema Germ Not cla <u>Comp</u>	cell mutagenicity assified based on ava conents:		from similar materials
Rema Germ Not cla Comp Ezetir	cell mutagenicity assified based on ava conents:	ailable information. : Test Type: Bad	cterial reverse mutation assay (AMES) vation: with and without metabolic activati
Rema Germ Not cla Comp Ezetir	cell mutagenicity assified based on ava conents: mibe:	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi	cterial reverse mutation assay (AMES) vation: with and without metabolic activati ve romosomal aberration łuman lymphocytes
Rema Germ Not cla <u>Comp</u> Ezetir Genot	cell mutagenicity assified based on ava <u>ponents:</u> mibe: toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chr Test system: H Result: negativ	cterial reverse mutation assay (AMES) vation: with and without metabolic activati ve romosomal aberration tuman lymphocytes ve
Rema Germ Not cla <u>Comp</u> Ezetir Genot	cell mutagenicity assified based on ava conents: mibe:	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic	cterial reverse mutation assay (AMES) vation: with and without metabolic activative romosomal aberration luman lymphocytes ve
Rema Germ Not cla <u>Comp</u> Ezetir Genot	cell mutagenicity assified based on ava <u>ponents:</u> mibe: toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic Species: Mous	cterial reverse mutation assay (AMES) vation: with and without metabolic activat ve romosomal aberration luman lymphocytes ve cronucleus test
Rema Germ Not cla <u>Comp</u> Ezetir Genot	cell mutagenicity assified based on ava <u>ponents:</u> mibe: toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic Species: Mous Cell type: Bond	cterial reverse mutation assay (AMES) vation: with and without metabolic activative romosomal aberration duman lymphocytes ve cronucleus test se e marrow
Rema Germ Not cla <u>Comp</u> Ezetir Genot	cell mutagenicity assified based on ava <u>ponents:</u> mibe: toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic Species: Mous	cterial reverse mutation assay (AMES) vation: with and without metabolic activative romosomal aberration duman lymphocytes ve cronucleus test se e marrow ute: Oral
Rema Germ Not cla Comp Ezetir Genot	cell mutagenicity assified based on ava <u>conents:</u> mibe: toxicity in vitro	<ul> <li>ailable information.</li> <li>Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ</li> <li>Test Type: Mic Species: Mous Cell type: Bond Application Ro Result: negativ</li> </ul>	cterial reverse mutation assay (AMES) vation: with and without metabolic activative romosomal aberration duman lymphocytes ve cronucleus test se e marrow ute: Oral
Rema Germ Not cla Comp Ezetir Genot	cell mutagenicity assified based on ava <u>ponents:</u> mibe: toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic Species: Mous Cell type: Bond Application Ro Result: negativ e: : Test Type: Bac	cterial reverse mutation assay (AMES) vation: with and without metabolic activative romosomal aberration tuman lymphocytes ve cronucleus test se e marrow ute: Oral ve
Rema Germ Not cla Comp Ezetir Genot	cell mutagenicity assified based on ava <u>conents:</u> mibe: toxicity in vitro toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic Species: Mous Cell type: Bond Application Ro Result: negativ e: : Test Type: Bac	cterial reverse mutation assay (AMES) vation: with and without metabolic activative romosomal aberration luman lymphocytes ve cronucleus test se e marrow ute: Oral ve cterial reverse mutation assay (AMES) D Test Guideline 471
Rema Germ Not cla Comp Ezetir Genot	cell mutagenicity assified based on ava <u>conents:</u> mibe: toxicity in vitro toxicity in vitro	ailable information. : Test Type: Bac Metabolic activ Result: negativ Test Type: Chi Test system: H Result: negativ : Test Type: Mic Species: Mous Cell type: Bond Application Ro Result: negativ e: : Test Type: Bac Method: OECE Result: negativ	cterial reverse mutation assay (AMES) vation: with and without metabolic activat ve romosomal aberration luman lymphocytes ve cronucleus test se e marrow ute: Oral ve cterial reverse mutation assay (AMES) D Test Guideline 471

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



sion	Revision Date: 06.04.2024		Number: 33-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
Genot	toxicity in vivo	S A	Fest Type: Roo Species: Mous Application Ro Result: negativ	ute: Ingestion
2-Pyr	rolidone:			
Genot	toxicity in vitro		Fest Type: Bac Result: negativ	eterial reverse mutation assay (AMES)
		N F	Method: OECD Result: negativ	itro mammalian cell gene mutation test 9 Test Guideline 476 e ed on data from similar materials
		Ν		omosome aberration test in vitro ) Test Guideline 473 e
Genot	toxicity in vivo		cytogenetic ass Species: Mous Application Ro	e ute: Intraperitoneal injection
			Result: negativ	) Test Guideline 474 e
Carci	nogenicity			
	<b>nogenicity</b> assified based on av	F	Result: negativ	
Not cl	• •	F	Result: negativ	
Not cl	assified based on av ponents:	F	Result: negativ	
Not cl <u>Comp</u> Ezetir Specie	assified based on av ponents: mibe: es	F ailable in : F	Result: negativ formation. Rat, female	
Not cl Comp Ezetir Specie Applic	assified based on av <u>conents:</u> mibe: es cation Route	F ailable in : F : c	Result: negativ formation. Rat, female oral (feed)	
Not cl Comp Ezetir Specie Applic	assified based on av <u>conents:</u> mibe: es cation Route sure time	F ailable in : F : c : 1	Result: negativ formation. Rat, female	
Not cl <u>Comp</u> Ezetir Specie Applic Expos Resul	assified based on av <u>conents:</u> mibe: es cation Route sure time t	F ailable in : F : c : 1 : r	Result: negativ formation. Rat, female oral (feed) 104 weeks negative	
Not cl Comp Ezetir Specie Applic Expos Result	assified based on av <u>conents:</u> mibe: es cation Route sure time t es	F ailable in : F : c : 1 : r : F	Result: negativ formation. Rat, female oral (feed) 104 weeks negative Rat, male	
Not cl Comp Ezetir Specie Applic Expos Result Specie Applic	assified based on av <u>conents:</u> mibe: es cation Route sure time t	F ailable in : F : c : 1 : r : F : c	Result: negativ formation. Rat, female oral (feed) 104 weeks negative	
Not cl Comp Ezetir Specie Applic Expos Result Specie Applic	assified based on av <u>conents:</u> mibe: es cation Route sure time t es cation Route sure time	F ailable in : F : c : 1 : r : r : c : 1	Result: negativ formation. Rat, female oral (feed) 104 weeks negative Rat, male oral (feed)	
Not cl. Comp Ezetin Specie Applic Expos Result Specie Applic Expos Result Specie Specie Specie	assified based on av <u>ponents:</u> mibe: es cation Route sure time t es cation Route sure time t es	F ailable in : F : c : 1 : r : f : c : 1 : r : N	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 104 weeks negative Mouse	
Not cl. Comp Ezetin Specie Applic Expos Resul Specie Applic Expos Resul Specie Applic	assified based on av <u>conents:</u> mibe: es cation Route sure time t es cation Route sure time t es cation Route sure time t	F ailable in : F : c : 1 : r : c : 1 : r : n : n : n : n	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 104 weeks negative Mouse oral (feed)	
Not cl. Comp Ezetin Specie Applic Expos Resul Specie Applic Expos Resul Specie Applic	assified based on av <u>conents:</u> mibe: es cation Route sure time t es cation Route sure time t es cation Route sure time t	F ailable in : F : c : 1 : r : 7 : 1 : 7 : 1 : 7 : 1 : 7 : 1 : 1 : 1	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 104 weeks negative Mouse	
Not cl. Comp Ezetin Specie Applic Expos Resul Specie Applic Expos Resul Specie Applic Expos Resul	assified based on av <u>conents:</u> mibe: es cation Route sure time t es cation Route sure time t es cation Route sure time t	F ailable in : F : c : 1 : r : 1 : r : 1 : r : 1 : r : 1 : r	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 04 weeks negative Mouse oral (feed) 04 weeks	
Not cl. Comp Ezetir Specie Applic Expos Result Specie Applic Expos Result Specie Applic Expos Result Specie Applic Expos Result	assified based on av <u>conents:</u> mibe: es cation Route sure time t es cation Route sure time t es cation Route sure time t um n-dodecyl sulfat	F ailable in : F : c : 1 : r : F : c : 1 : r : N : c : 1 : r	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 04 weeks negative Mouse oral (feed) 04 weeks negative	
Not cl Comp Ezetir Specie Applic Expos Result Specie Result Specie Result Specie Result	assified based on av <u>conents:</u> mibe: es cation Route sure time t es cation Route sure time t es cation Route sure time t um n-dodecyl sulfat	F ailable in : F : C : 1 : r : F : C : 1 : r : N : C : 1 : r : T : F : C : 1 : r : F : C : 1 : r : F : C : 1 : T : C : 1 : T : C : 1 : T : C : 1 : C : 1 : T : C : 1 : 1 : C : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 04 weeks negative Mouse oral (feed) 04 weeks	
Not cl. Comp Ezetin Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos Result Specia Applic Expos	assified based on av <u>ponents:</u> mibe: es cation Route sure time t es cation Route sure time t mn-dodecyl sulfat es cation Route sure time t	F ailable in : F : c : 1 : r : F : c : 1 : r : 1 : r : 1 : r : 1 : r : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 2	Result: negativ formation. Rat, female oral (feed) 04 weeks negative Rat, male oral (feed) 04 weeks negative Mouse oral (feed) 04 weeks negative	e

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



ersion 2	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
Resul Rema		: negative : Based on data	a from similar materials
2-Pyr	rolidone:		
	cation Route sure time t	: Mouse : Ingestion : 18 month(s) : negative : Based on data	a from similar materials
Repro	oductive toxicity		
Not cl	assified based on avai	able information.	
<u>Comp</u>	oonents:		
Ezetii	mibe:		
Effect	s on fertility	Species: Rat, Fertility: NOAE	rtility/early embryonic development male and female EL: > 1,000 mg/kg body weight ects on fertility, No fetotoxicity
Effect ment	s on foetal develop-	: Test Type: De Species: Rat Application Ro Developmenta Result: No adv	oute: Oral al Toxicity: NOAEL: > 1,000 mg/kg body weigh
		Test Type: De Species: Rabb Application Ro Developmenta Result: No adv	bit bute: Oral al Toxicity: NOAEL: > 1,000 mg/kg body weigh
Sodiu	Im n-dodecyl sulfate:		
	s on fertility	Species: Rat Application Ro Method: OECI Result: negativ	D Test Guideline 416
Effect ment	s on foetal develop-	Species: Rat Application Ro Result: negativ	
2-Pvr	rolidone:		
-	s on fertility	: Test Type: On Species: Rat	e-generation reproduction toxicity study

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



ersion 2	Revision Date: 06.04.2024		DS Number: 833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
			Application Rou	
			Result: positive Remarks: Base	d on data from similar materials
Effect ment	s on foetal develop-	:	Test Type: Emb Species: Rat Application Rou	oryo-foetal development
			Result: positive	
Repro sessn	oductive toxicity - As- nent	:	ity, based on ar	of adverse effects on sexual function and fert nimal experiments., Clear evidence of adverse lopment, based on animal experiments.
	<b>- single exposure</b> assified based on avai	lable	information.	
STOT	- repeated exposure			
Not cl	assified based on avai	lable	information.	
Repe	ated dose toxicity			
<u>Com</u>	oonents:			
Ezetii	mibe:			
Speci		:	Dog	
NOAE		:	1,000 mg/kg	
	cation Route	÷	Oral	
Rema	sure time	:	90 d	dvorse offects were reported
Reina	1172	•	NU Significant a	dverse effects were reported
Speci	es	:	Rat	
NOAE	EL	:	1,500 mg/kg	
	cation Route	:	Oral	
	sure time	:	90 d	
Rema	urks	:	No significant a	dverse effects were reported
Speci	es	:	Mouse	
NOAE		:	500 mg/kg	
	cation Route	:	Oral	
	sure time	:	90 d	Lange Martin and a land
Rema	Irks	:	No significant a	dverse effects were reported
Speci		:	Dog	
NOAE		:	300 mg/kg	
Annlic	cation Route	:	Oral	
			1 yr	dverse effects were reported
Expos	sure time		No oignificant o	
		:	No significant a	
Expos Rema		:	No significant a	
Expos Rema	ırks ı <mark>m n-dodecyl sulfate</mark> :	:	Rat	
Expos Rema Sodiu Speci NOAE	ırks <b>ım n-dodecyl sulfate:</b> es	:	,	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Ezetimibe Formulation**

Version 4.2	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
Expo Rema	sure time arks	: 90 Days : Based on data	a from similar materials
2-Pyi	rolidone:		
Spec NOAI Appli	ies EL cation Route sure time	: Rat : 207 mg/kg : Ingestion : 3 Months : OECD Test G	uideline 408
-	r <b>ation toxicity</b> lassified based on ava	ailable information.	
	ponents:		
	mibe:		
	pplicable		
11.2 Infor	mation on other haz	ards	
Endo	ocrine disrupting pro	perties	
Prod	uct:		
Asse	ssment	ered to have e REACH Article	e/mixture does not contain components consid- endocrine disrupting properties according to e 57(f) or Commission Delegated regulation 00 or Commission Regulation (EU) 2018/605 at or higher.
Expe	rience with human e	xposure	
<u>Com</u>	ponents:		
Ezeti	mibe:		
Inges	tion		eadache, Nausea, Vomiting, Diarrhoea, flatu- pain, upper respiratory tract infection, Back n
SECTION	N 12: Ecological in	formation	
12.1 Toxi	city		
<u>Com</u>	ponents:		
Ezeti	mibe:		
Toxic	ity to fish	Exposure time Method: OEC	nales promelas (fathead minnow)): > 0.125 mg/l e: 96 h D Test Guideline 203

Toxicity to daphnia and other	:	EC50 (Daphnia magna (Water flea)): > 4 mg/l

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versic 4.2	on	Revision Date: 06.04.2024		S Number: 333-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
а	quatic	invertebrates		Exposure time: 48 Method: OECD Te Remarks: No toxic	
	oxicity lants	to algae/aquatic	:	0.317 mg/l Exposure time: 96 Method: OECD Te	
				mg/l Exposure time: 96 Method: OECD Te	
Т	oxicity	to microorganisms	:	EC50 : > 4.4 mg/l Exposure time: 3 l Test Type: Respir Method: OECD Te Remarks: No toxic	ation inhibition
				NOEC : 4.4 mg/l Exposure time: 3 l Test Type: Respir Method: OECD Te Remarks: No toxic	ation inhibition
	oxicity city)	to fish (Chronic tox-	:	NOEC: 0.051 mg/ Exposure time: 33 Species: Pimepha Method: OECD Te	d Iles promelas (fathead minnow)
					d Ion variegatus (sheepshead minnow) sity at the limit of solubility
а		to daphnia and other invertebrates (Chron- y)	:		
	/I-Facto oxicity)	or (Chronic aquatic	:	1	
		n n-dodecyl sulfate: to fish	:	LC50 (Pimephales Exposure time: 96	s promelas (fathead minnow)): 29 mg/l s h
		to daphnia and other invertebrates	:	EC50 (Ceriodaphr Exposure time: 48	nia dubia (water flea)): 5.55 mg/l 8 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Vers 4.2	ion	Revision Date: 06.04.2024		0S Number: 833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014		
	Toxicity plants	v to algae/aquatic	:	ErC50 (Desmodes Exposure time: 72	smus subspicatus (green algae)): > 120 mg/l ? h		
				NOEC (Desmode: Exposure time: 72	smus subspicatus (green algae)): 30 mg/l ? h		
	Toxicity	to microorganisms	:	EC50 : 135 mg/l Exposure time: 3 l	h		
	Toxicity icity)	to fish (Chronic tox-	:	NOEC: >= 1.357 mg/l Exposure time: 42 d Species: Pimephales promelas (fathead minnow)			
		to daphnia and other invertebrates (Chron- ty)	:	NOEC: 0.88 mg/l Exposure time: 7 d Species: Ceriodaphnia dubia (water flea)			
	2-Pvrrc	blidone:					
	Toxicity		:	LC50 (Danio rerio Exposure time: 96 Method: OECD Te			
		v to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): > 500 mg/l 8 h		
	Toxicity plants	v to algae/aquatic	:	: ErC50 (Desmodesmus subspicatus (green algae)): > Exposure time: 72 h			
				EC10 (Desmodes Exposure time: 72	mus subspicatus (green algae)): 22.2 mg/l ? h		
	Toxicity	to microorganisms	:	EC50 : > 1,000 m Exposure time: 30 Method: OECD Te	min		
12.2	Persist	tence and degradabil	ity				
	Compo	onents:					
	Ezetim	ibe:					
		rodobility		Decult: Not readily	, biodogradabla		

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 6.8 % Exposure time: 28 d
Stability in water	:	Hydrolysis: 50 %(4.5 d) Method: OECD Test Guideline 111
Sodium n-dodecyl sulfate:		

Biodegradability	:	Result: Readily biodegradable.
		Biodegradation: 95 %
		Exposure time: 28 d

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 4.2	Revision Date: 06.04.2024		0S Number: 833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
			Method: OECD	Test Guideline 301B
-	r <b>olidone:</b> egradability	:	Result: Readily Remarks: Base	biodegradable. d on data from similar materials
12.3 Bioa	ccumulative potential			
Com	ponents:			
Ezeti	mibe:			
Bioac	cumulation	:	Exposure time: Bioconcentratio	nis macrochirus (Bluegill sunfish) 97 d n factor (BCF): 173 Test Guideline 305
	ion coefficient: n- ol/water	:	log Pow: 4.36	
Sodi	um n-dodecyl sulfate:			
	ion coefficient: n- ol/water	:	log Pow: 0.83	
2-Pyr	rolidone:			
	ion coefficient: n- ol/water	:	log Pow: -0.71 Method: OECD	Test Guideline 107
12.4 Mobi	lity in soil			
Com	ponents:			
Ezeti	mibe:			
	bution among environ- al compartments	:	log Koc: 4.35 Method: OECD	Test Guideline 106
12.5 Resu	ilts of PBT and vPvB a	isse	ssment	
Prod	uct:			
Asse	ssment	:	to be either per	mixture contains no components considered sistent, bioaccumulative and toxic (PBT), or and very bioaccumulative (vPvB) at levels of
12.6 Endo	ocrine disrupting prop	ertie	S	
Prod	uct:			
	ssment	:	ered to have en REACH Article	mixture does not contain components consid- docrine disrupting properties according to 57(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Ezetimibe Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

### 13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

### 14.1 UN number or ID number

ADN	:	UN 3077	
ADR	:	UN 3077	
RID	:	UN 3077	
IMDG	:	UN 3077	
ΙΑΤΑ	:	UN 3077	
14.2 UN proper shipping name			
ADN	:	ENVIRONMENTALLY N.O.S. (Ezetimibe)	Y HAZARDOUS SUBSTANCE, SOLID,
ADR	:	ENVIRONMENTALLY N.O.S. (Ezetimibe)	Y HAZARDOUS SUBSTANCE, SOLID,
RID	:	ENVIRONMENTALLY N.O.S. (Ezetimibe)	Y HAZARDOUS SUBSTANCE, SOLID,
IMDG	:	ENVIRONMENTALLY N.O.S. (Ezetimibe)	Y HAZARDOUS SUBSTANCE, SOLID,
ΙΑΤΑ	:	Environmentally haza (Ezetimibe)	ardous substance, solid, n.o.s.
14.3 Transport hazard class(es	5)		
		Class	Subsidiary risks
ADN	:	9	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 4.2	Revision Date: 06.04.2024		S Number: 333-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
ADI	۶	:	9	
RID		:	9	
IMD	G	:	9	
IAT	A	:	9	
14.4 Pac	king group			
Clas	king group ssification Code ard Identification Number	:	III M7 90 9	
Clas Haz Lab	king group ssification Code ard Identification Number		III M7 90 9 (-)	
Clas	king group ssification Code ard Identification Number	:	III M7 90 9	
Lab	king group	:	III 9 F-A, S-F	
Pac airc Pac	king instruction (LQ) king group	:	956 Y956 III Miscellaneous	
IAT Pac ger	A (Passenger) king instruction (passen- aircraft)	:	956	
Pac Pac Lab	king instruction (LQ) king group els	:	Y956 III Miscellaneous	
14.5 Env	vironmental hazards			
<b>ADI</b> Env	N ironmentally hazardous	:	yes	
<b>ADI</b> Env	<b>R</b> ironmentally hazardous	:	yes	
<b>RID</b> Env	ironmentally hazardous	:	yes	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Ezetimibe Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014
<b>IMDG</b> Marin	i e pollutant	: yes	
ΙΑΤΑ	(Passenger) onmentally hazardous	: yes	
	<b>(Cargo)</b> onmentally hazardous	: yes	

#### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

uiu				
	REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances,	:	Not applicable	
	mixtures and articles (Annex XVII)			
	REACH - Candidate List of Substances of Very High	:	Not applicable	
	Concern for Authorisation (Article 59).			
	Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable	
	plete the ozone layer			
	Regulation (EU) 2019/1021 on persistent organic pollu-	:	Not applicable	
	tants (recast)			
	Regulation (EU) No 649/2012 of the European Parlia-	:	Not applicable	
	ment and the Council concerning the export and import			
	of dangerous chemicals			
	REACH - List of substances subject to authorisation	:	Not applicable	
	(Annex XIV)			
	Seveso III: Directive 2012/18/EU of the European Parlian		and of the Council	on the control of
	major-accident hazards involving dangerous substances.	•		
			Quantity 1	Quantity 2

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL	200 t	500 t
	HAZARDS		

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Ezetimibe Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Number: 23833-00024	Date of last issue: 26.09.2023 Date of first issue: 21.10.2014			
SECTION	16: Other information	ation				
Other information :			Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.			
Full t	ext of H-Statements					
H302 H315 H318 H319 H360 H410 H412	FD	<ul> <li>Causes skin i</li> <li>Causes seriol</li> <li>Causes seriol</li> <li>Causes seriol</li> <li>May damage</li> <li>Very toxic to a</li> </ul>	<ul> <li>Harmful if swallowed.</li> <li>Causes skin irritation.</li> <li>Causes serious eye damage.</li> <li>Causes serious eye irritation.</li> <li>May damage fertility. May damage the unborn child.</li> <li>Very toxic to aquatic life with long lasting effects.</li> <li>Harmful to aquatic life with long lasting effects.</li> </ul>			
Full t	ext of other abbrevia	ations				
Acute Aquat Eye I Eye Iı Repr. Skin I IE OE	tic Chronic Dam. rrit. rrit.	: Serious eye c : Eye irritation : Reproductive : Skin irritation : Ireland. List o	nronic) aquatic hazard lamage			
IE OE	EL / OELV - 8 hrs (TW		exposure limit value (8-hour reference period)			

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Ezetimibe Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
4.2	06.04.2024	23833-00024	Date of first issue: 21.10.2014

Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### **Further information**

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

#### **Classification of the mixture:**

### Classification procedure:

Aquatic Chronic 2	H411	Calculation method
-------------------	------	--------------------

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN